Nearly €50 Million Worth of Vaccines Destroyed or Returned Unused by HSE in Two Years

In a significant revelation about public health resource management, the Health Service Executive (HSE) in Ireland reported that nearly €50 million worth of vaccines were either destroyed or returned unused over a two-year period. This figure underscores ongoing challenges in vaccine forecasting, storage logistics, and demand planning within national immunization programs.

Understanding the Scale of Vaccine Wastage

According to official HSE data released in response to parliamentary questions, approximately €49.8 million in vaccines were not administered between 2022 and 2024. This includes vaccines that expired before use, were compromised due to cold chain breaches, or were returned to suppliers after being deemed surplus to requirements.

The majority of the wastage involved seasonal influenza vaccines, with significant quantities also attributed to COVID-19 booster doses and childhood immunization stocks. Factors contributing to the waste include over-ordering based on predictive models, last-minute changes in public health guidance, and logistical hurdles in distributing vaccines to general practitioners and pharmacies.

Causes Behind Unused Vaccine Stockpiles

Several interconnected factors led to the high levels of unused vaccines:

• Overestimation of demand: Initial procurement volumes for flu and COVID-19 vaccines were based on peak pandemic-era uptake rates, which did not sustain at the same levels in subsequent seasons.
• Short shelf lives: Many vaccines, particularly mRNA-based formulations, have limited stability once thawed or reconstituted, creating narrow windows for administration.
• Storage and handling issues: Maintaining the required cold chain (typically between 2°C and 8°C) is critical. Any deviation can render doses ineffective, necessitating disposal.
• Administrative delays: In some cases, vaccines arrived at healthcare facilities too close to their expiry dates to be used effectively.

Experts note that while some level of vaccine wastage is inevitable in large-scale immunization campaigns, the scale observed in Ireland raises questions about procurement strategies and real-time inventory management.

Financial and Public Health Implications

The financial cost of nearly €50 million represents a substantial portion of the HSE’s annual vaccines budget. For context, the total expenditure on vaccines and immunization services in 2023 was approximately €120 million, meaning almost half of that year’s allocation was effectively lost to wastage.

Beyond the monetary impact, unused vaccines represent missed opportunities to protect vulnerable populations. Public health officials emphasize that every dose not administered is a potential gap in community immunity, particularly for diseases like influenza, which causes hundreds of deaths annually in Ireland, especially among older adults and those with chronic conditions.

Steps Taken to Reduce Future Wastage

In response to the findings, the HSE has implemented several measures aimed at improving vaccine management:

• Enhanced forecasting models using real-time uptake data from general practices and pharmacies.
• More frequent, smaller-volume deliveries to reduce the risk of expiry.
• Improved temperature monitoring systems with real-time alerts for cold chain deviations.
• Greater flexibility in vaccine allocation, allowing redistribution between regions based on demand.
• Collaboration with the Health Products Regulatory Authority (HPRA) to explore extended use protocols for certain vaccines under strict conditions.

the HSE has increased transparency by publishing quarterly reports on vaccine inventory and wastage, enabling better oversight and public accountability.

International Context: How Ireland Compares

Vaccine wastage is not unique to Ireland. Similar challenges have been reported across Europe and globally. For example, the European Centre for Disease Prevention and Control (ECDC) noted in its 2023 report that several member states experienced influenza vaccine wastage rates exceeding 20% during the 2022–2023 season, often due to overprocurement and late-season delivery.

The World Health Organization (WHO) estimates that globally, up to 50% of vaccines may be wasted in some low- and middle-income countries due to infrastructure limitations. In high-income nations like Ireland, wastage tends to stem more from overestimation and logistical inefficiencies than from inadequate cold chain capacity.

Nonetheless, even in well-resourced settings, minimizing waste is critical to ensuring equitable access and maintaining public trust in immunization programs.

The Way Forward: Smarter Vaccine Management

Moving forward, experts advocate for a shift toward just-in-time vaccine supply chains, supported by digital inventory tracking and artificial intelligence-driven demand forecasting. Integrating electronic health records with immunization databases could allow for more accurate predictions of who needs which vaccine and when.

There is also growing support for modular vaccine manufacturing and regional stockpiling, which could allow faster responses to outbreaks without the risk of large-scale expiration.

As Dr. Lucy Jessop, Director of the National Immunisation Office at the HSE, stated in a recent briefing: “We are learning from these challenges. The goal is not to eliminate all wastage — which may be impossible in dynamic public health environments — but to reduce it to the lowest clinically acceptable level through smarter planning and real-time adaptation.”

Key Takeaways

• The HSE reported nearly €50 million in vaccines destroyed or returned unused between 2022 and 2024.
• Seasonal flu and COVID-19 vaccines made up the largest portions of wasted stock.
• Primary causes include overestimation of demand, short shelf lives, and cold chain challenges.
• The financial loss represents a significant portion of Ireland’s annual vaccines budget.
• New measures include improved forecasting, smaller deliveries, and real-time temperature monitoring.
• International comparisons show similar trends, though causes vary by income level and infrastructure.

Ongoing efforts focus on leveraging technology and data to create more responsive, efficient vaccine supply chains.

Frequently Asked Questions (FAQ)

Why were so many vaccines wasted in Ireland?

The main reasons were overordering based on inflated demand forecasts, limited shelf life of certain vaccines (especially mRNA types), and challenges in maintaining the cold chain during distribution and storage.

Which vaccines were most commonly wasted?

Seasonal influenza vaccines accounted for the largest share, followed by COVID-19 booster doses. Childhood vaccines showed lower wastage rates due to more stable demand patterns.

Is vaccine wastage a sign of poor planning?

While some wastage is unavoidable in public health emergencies, the scale observed suggests room for improvement in forecasting, inventory management, and supply chain agility.

What is the HSE doing to prevent this from happening again?

The HSE has introduced real-time uptake tracking, smaller and more frequent deliveries, improved cold chain monitoring, and greater flexibility in redistributing vaccines across regions.

How does Ireland’s vaccine wastage compare to other countries?

Similar wastage rates have been seen in other high-income countries, particularly during seasonal flu campaigns. In low-resource settings, wastage is often higher due to infrastructure limitations, whereas in Ireland, it is more closely tied to overprocurement and timing issues.

Can unused vaccines ever be safely used after expiration?

No. Once a vaccine passes its expiration date or has been stored outside recommended temperatures, it cannot be used, as its potency and safety cannot be guaranteed.